home > news > detailed info

Ethypharm and RSSL partnership fast-tracks priority medicine


The European based specialty pharmaceutical company, Ethypharm, collaborated with Reading Scientific Services Ltd (RSSL) to accelerate the manufacture and batch release of fentanyl injection; one of the critical medicines needed for the treatment of COVID-19 patients.

As a major supplier of essential medicines to the NHS, Ethypharm responded to requests from the Department of Health and Social Care (DHSC) for increased volumes of priority medicines by changing its production schedule to meet this urgent need.

“We took the decision to dedicate production at our Romford facility to COVID-19 critical medicines for a three-week period - with one line used for fentanyl injection alone. We had outstanding commitment and performance from our staff on site, but we needed to be confident that these unprecedented quantities could be delivered to the front-line within the shortest time frame possible, without impacting patient safety.

“This was only achieved thanks to the exceptional support and professional approach of RSSL, who once again demonstrated why they remain one of our highly trusted partners,” explained Phil Parry, UK General Manager at Ethypharm.

RSSL reduced the conventional 6-8 week timeframe to just seven days - and provided rapid analytical and sterility test services. This agile response enabled Ethypharm to achieve an ambitious lead time of 28 days from manufacture to batch release - much faster than under normal operating conditions.

“Our ability to flex and adapt to our clients’ needs was central to this project’s success - as was the speed of our response. This meant redirecting resources across our 7 day a week operation - but without compromising any of the stringent measures we have put in place to maintain a COVID-19 work-safe environment for our teams nor the quality of our scientific rigour,” said Jacinta George, Managing Director for RSSL.

Ethypharm has now resumed business-as-usual operations at normal volumes across its full hospital product range, but is poised to repeat this emergency response plan in the event of a second peak of COVID-19 infections.

RSSL will continue to work with Ethypharm as one of its key partners. The two companies enjoy a strong working relationship, with RSSL’s specialised testing services particularly valued. More recently, RSSL has collaborated with Ethypharm on a strategic level related to the improvement and expansion of production capacity at the Romford site.


Press Contacts:
Reading Scientific Services Limited
Rachel Horton (Marketing Manager)
Email – or Tel - +44(0) 1189 184 024

Beverley Thompson (HR & Communication Director, UK)
Email - or Tel - +44 (0) 1628 551 923

Link to news story on RSSL website: 
phone +44 (0)118 918 4024
email University of Reading, Whiteknights Rd, Reading, West Berkshire RG6 6LA
Print this page
Send to a friend
News and Press Releases


For its fifth annual Europe conference, FlyPharma chose Copenhagen as its host city to address the latest supply chain challenges and industry best practices, putting together a global audience of (bio)pharma and logistics professionals. The two-day conference (22-23 October 2019) aimed to discuss the collaboration and growth within Scandinavia, with a special focus on women in pharmaceutical logistics and an exploration of the industry’s digitalisation and innovation.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B


Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement